|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
RS63430B1
(sr)
|
2010-10-01 |
2022-08-31 |
Modernatx Inc |
Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK3682905T3
(da)
|
2011-10-03 |
2022-02-28 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
|
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
CA2866955A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
SG10201710631RA
(en)
|
2012-03-27 |
2018-02-27 |
Curevac Ag |
Artificial nucleic acid molecules for improved protein or peptide expression
|
|
SG11201405545XA
(en)
|
2012-03-27 |
2014-11-27 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
SG10201710473VA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
RU2712743C2
(ru)
|
2013-08-21 |
2020-01-30 |
Куревак Аг |
Вакцина против бешенства
|
|
WO2015024669A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Combination vaccine
|
|
WO2015024668A2
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Respiratory syncytial virus (rsv) vaccine
|
|
CN105451779A
(zh)
|
2013-08-21 |
2016-03-30 |
库瑞瓦格股份公司 |
增加rna编码蛋白表达的方法
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
CN105874072A
(zh)
*
|
2013-12-30 |
2016-08-17 |
库瑞瓦格股份公司 |
人工核酸分子
|
|
WO2015101416A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Methods for rna analysis
|
|
EP3090053B1
(en)
|
2013-12-30 |
2018-11-21 |
CureVac AG |
Artificial nucleic acid molecules
|
|
EP3415629A1
(en)
*
|
2013-12-30 |
2018-12-19 |
CureVac AG |
Artificial nucleic acid molecules
|
|
US10307472B2
(en)
|
2014-03-12 |
2019-06-04 |
Curevac Ag |
Combination of vaccination and OX40 agonists
|
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
KR102459599B1
(ko)
|
2014-06-10 |
2022-10-26 |
큐어백 리얼 이스테이트 게엠베하 |
Rna생산을 증진하는 방법 및 수단
|
|
PT3766916T
(pt)
|
2014-06-25 |
2022-11-28 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
|
DK3708668T3
(da)
*
|
2014-12-12 |
2022-09-26 |
Curevac Ag |
Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
|
|
WO2016107877A1
(en)
*
|
2014-12-30 |
2016-07-07 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
|
CN108064176A
(zh)
|
2015-04-22 |
2018-05-22 |
库瑞瓦格股份公司 |
用于治疗肿瘤疾病的含有rna的组合物
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
EP3289101B1
(en)
|
2015-04-30 |
2021-06-23 |
CureVac AG |
Immobilized poly(n)polymerase
|
|
EP3294885B1
(en)
|
2015-05-08 |
2020-07-01 |
CureVac Real Estate GmbH |
Method for producing rna
|
|
CN104789527B
(zh)
*
|
2015-05-15 |
2018-05-29 |
江苏杰晟生物科技有限公司 |
一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品
|
|
BR112017017949A2
(pt)
|
2015-05-15 |
2018-04-10 |
Curevac Ag |
regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
|
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
EP3298142B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
DK4108769T3
(da)
|
2015-05-29 |
2023-10-09 |
Curevac Mfg Gmbh |
Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
|
|
WO2016193226A1
(en)
|
2015-05-29 |
2016-12-08 |
Curevac Ag |
Method for adding cap structures to rna using immobilized enzymes
|
|
AU2016285852B2
(en)
|
2015-06-29 |
2020-12-17 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
DK3112469T3
(en)
|
2015-06-30 |
2018-05-07 |
Ethris Gmbh |
EXPRESSIONS TO INCREASE THE TRANSLATION EFFECTIVENESS OF RNA MOLECULES
|
|
WO2017001058A1
(en)
*
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
|
EP3334828B1
(en)
*
|
2015-08-10 |
2020-10-28 |
CureVac Real Estate GmbH |
Method of increasing the replication of a circular dna molecule
|
|
EP4108774A1
(en)
*
|
2015-08-28 |
2022-12-28 |
CureVac AG |
Artificial nucleic acid molecules
|
|
WO2017049245A2
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066793A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
LT3368507T
(lt)
|
2015-10-28 |
2023-03-10 |
Acuitas Therapeutics Inc. |
Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui
|
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
|
WO2017109134A1
(en)
|
2015-12-22 |
2017-06-29 |
Curevac Ag |
Method for producing rna molecule compositions
|
|
ES2913626T5
(en)
|
2015-12-22 |
2025-05-12 |
Modernatx Inc |
Compounds and compositions for intracellular delivery of agents
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
MX2018009917A
(es)
|
2016-02-17 |
2019-08-14 |
Curevac Ag |
Vacuna contra el virus del zika.
|
|
WO2017149139A1
(en)
|
2016-03-03 |
2017-09-08 |
Curevac Ag |
Rna analysis by total hydrolysis
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
CA3020343A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
EP4477662A3
(en)
|
2016-05-04 |
2025-03-19 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
CN109475640B
(zh)
|
2016-06-09 |
2023-03-10 |
库瑞瓦格欧洲公司 |
核酸被运载物的混合载运体
|
|
AU2017286606A1
(en)
|
2016-06-14 |
2018-12-13 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018013525A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
EP3548005A4
(en)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
JP2020501545A
(ja)
|
2016-12-08 |
2020-01-23 |
キュアバック アーゲー |
肝疾患の処置または予防のためのrna
|
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
|
MX2019008303A
(es)
|
2017-01-11 |
2019-12-02 |
Univ Pennsylvania |
Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
|
|
WO2018170336A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
WO2018172556A1
(en)
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
CA3057394A1
(en)
|
2017-04-14 |
2018-10-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
|
WO2018200892A1
(en)
|
2017-04-27 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
|
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
AU2018298422B2
(en)
*
|
2017-07-04 |
2023-04-06 |
CureVac SE |
Novel nucleic acid molecules
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CA3073018A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US20200362382A1
(en)
|
2017-08-18 |
2020-11-19 |
Modernatx, Inc. |
Methods of preparing modified rna
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
JP7275111B2
(ja)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
SG11202005760PA
(en)
|
2017-12-21 |
2020-07-29 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
EP3737424A4
(en)
|
2018-01-10 |
2021-10-27 |
Translate Bio MA, Inc. |
COMPOSITIONS AND METHODS TO FACILITATE THE DELIVERY OF SYNTHETIC NUCLEIC ACIDS INTO CELLS
|
|
EP4227319B1
(en)
|
2018-04-17 |
2025-11-26 |
CureVac SE |
Novel rsv rna molecules and compositions for vaccination
|
|
JP7352581B2
(ja)
|
2018-06-28 |
2023-09-28 |
キュアバック アールエヌエイ プリンター ゲーエムベーハー |
Rnaインビトロ転写用バイオリアクター
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
|
KR20210133218A
(ko)
|
2019-01-31 |
2021-11-05 |
모더나티엑스, 인크. |
볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
|
|
CA3128215A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
US12029786B2
(en)
*
|
2020-02-07 |
2024-07-09 |
RNAimmune, Inc. |
Composition and method of mRNA vaccines against novel coronavirus infection
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
EP4077272B1
(en)
|
2020-04-09 |
2024-09-18 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid nanoparticle composition
|
|
CN114206463B
(zh)
|
2020-06-30 |
2024-06-11 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
|
WO2022037652A1
(en)
|
2020-08-20 |
2022-02-24 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
KR20230164648A
(ko)
|
2020-12-22 |
2023-12-04 |
큐어백 에스이 |
SARS-CoV-2 변이체에 대한 RNA 백신
|
|
CN114717229B
(zh)
*
|
2021-01-05 |
2024-09-10 |
麦塞拿治疗(香港)有限公司 |
治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
|
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022247755A1
(en)
|
2021-05-24 |
2022-12-01 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
JP2024530672A
(ja)
|
2021-08-11 |
2024-08-23 |
アールエヌエーイミューン、インコーポレイテッド |
新規なコロナウイルス感染症に対するmRNAワクチンの組成物および方法
|
|
WO2023044333A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
JP2024534697A
(ja)
|
2021-09-14 |
2024-09-20 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
非環状脂質及びその使用方法
|
|
JP2024536406A
(ja)
|
2021-10-08 |
2024-10-04 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
US20250108007A1
(en)
|
2021-12-23 |
2025-04-03 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
|
WO2024097259A1
(en)
|
2022-11-01 |
2024-05-10 |
RNAimmune, Inc. |
Composition and methods for mrna vaccines against novel omicron coronavirus infections
|
|
CN116004696B
(zh)
*
|
2023-02-01 |
2024-03-29 |
郑州贝贝生物科技有限公司 |
可与IRES组合的3ˊUTR加茎环结构基因及其应用、mRNA表达系统
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|